Neuroendocrine Correlates of Leptin
Glucose and Insulin Increase the Transport of Leptin through the Blood-Brain Barrier in Normal Mice but Not in Streptozotocin-Diabetic MiceKastin A.J. · Akerstrom V.
VA Medical Center and Tulane University School of Medicine, New Orleans, La., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Since fasting is one of the few factors found to change the rate of entry of leptin into brain, we used multiple-time regression analysis to study the effects of pretreatment with glucose or insulin on leptin transport across the blood-brain barrier (BBB). Two hours after intraperitoneal injection of glucose (3 g/kg), there was a statistically significant increase in the entry rate (Ki) of leptin in fasted (from 4.91 ± 0.70 × 10–4 ml/g min to 9.03 ± 1.00 × 10–4 ml/g min) but not (p = 0.15) in nonfasted normal (from 4.90 ± 1.21 × 10–4 ml/g min to 6.42 ± 1.79 × 10–4 ml/g min) or fasted streptozotocin (STZ)-treated diabetic mice (from 4.043 ± 0.959 × 10–4 ml/g min to 5.395 ± 1.355 × 10–4 ml/g min). Insulin (10 U/kg) increased leptin influx in fasted (from 4.77 ± 0.26 × 10–4 ml/g min to 10.6 ± 0.15 × 10–4 ml/g min at 0.5 h) and nonfasted (from 4.64 ± 0.75 × 10–4 ml/g min to 7.46 ± 1.48 × 10–4 ml/g min at 0.5 h) normal mice, but not in STZ-diabetic mice deficient in insulin (and leptin), even though basal concentrations of glucose were similarly increased in the nonfasted normal and STZ-treated mice. Moreover, the basal rate of leptin influx was the same in overnight fasted normal mice, nonfasted normal mice and STZ-diabetic mice. The results indicate that glucose and insulin can increase leptin transport, but they probably are not the principal factors responsible for the regulatory effect of the BBB on leptin entry into the brain.
© 2001 S. Karger AG, Basel
- Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM: Leptin enters the brain by a saturable system independent of insulin. Peptides 1996;17:305–311.
- Bray GA, York DA: Leptin and clinical medicine: A new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997;82:2771–2776.
- Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang P-L, Sinha MK, Considine RV: Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 1996;348:159–161.
- Halaas J, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM: Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci 1997;94:8878–8883.
- Koistinen HA, Karonen S-L, Iivanainen M, Koivisto VA: Circulating leptin has saturable transport into intrathecal space in humans. Eur J Clin Invest 1998;28:894–897.
- Steiner RA: Editorial: Lords and ladies leapin’ on leptin. Endocrinology 1996;137:4533–4535.
- Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr: Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997;99:385–390.
- Wu-Peng XS, Chua SC Jr, Okada N, Liu S-M, Nicolson M, Leibel RL: Phenotype of obese Koletsky (f) rat due to Tyr763 stop mutation in the extracellular domain of the leptin receptor (lepr). Diabetes 1997;46:513–518.
- Kastin AJ, Akerstrom V: Fasting, but not adrenalectomy, reduces transport of leptin into the brain. Peptides 2000;21:679–682.
- Kastin AJ, Pan W, Maness LM, Banks WA: Peptides crossing the blood-brain barrier: Some unusual observations. Brain Res 1999;848:96–100.
- Harris RBS, Ramsay TG, Smith SR, Bruch RC: Early and late stimulation of ob mRNA expression in meal-fed and overfed rats. J Clin Invest 1996;97:2020–2026.
- Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF: Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol Metab 1996;81:4162–4165.
- Mizuno TM, Bergen H, Funahashi T, Kleopoulos SP, Zhong Y-G, Bauman WA, Mobbs CV: Obese gene expression: Reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquired (diet-induced) and genetic (yellow agouti) obesity. Proc Natl Acad Sci USA 1996;93:3434–3438.
- Saladin R, DeVos P, Guerre-Millo M, Leturque J, Staels GB, Auwerx J: Transient increase in obese gene expression after food intake or insulin administration. Nature 1995;377:527–529.
- Havel PJ, Uriu-Hare JY, Liu T, Stanhope KL, Stern JS, Keen CL, Ahren B: Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: Reversal by insulin. Am J Physiol 1998;274:R1482–R1491.
- MacDougald OA, Hwang C-S, Fan H, Lane MD: Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1995;92:9034–9037.
- Saad MF, Khan A, Sharma A, Michael R, Riad-Gabriel MG, Boyadjian R, Jinagouda SD, Steil GM, Kamdar V: Physiological insulinemia acutely modulates plasma leptin. Diabetes 1998;47:544–549.
- Becker DJ, Ongemba LN, Brichard V, Henquin JC, Brichard SM: Diet- and diabetes-induced changes of ob gene expression in rat adipose tissue. FEBS Lett 1995;371:324–328.
- Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM: Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med 1995;1:1155–1161.
- Sivitz WI, Bailey HL, Donohoue P: Rat Adipose ob mRNA levels in states of altered circulating glucose and insulin. Biochem Biophys Res Commun 1996;220:520–525.
- Trayhurn P, Thomas MEA, Duncan JS, Rayner DV: Effects of fasting and refeeding on ob gene expression in white adipose tissue of lean and obese (ob/ob) mice. FEBS Lett 1995;368:488–490.
Banks WA, Kastin AJ: Measurement of transport of cytokines across the blood-brain barrier; in Conn PM, De Souza EB (eds): Neurobiology of Cytokines, Part A. San Diego, Academic Press, 1993, pp 67–77.
- Ibayashi S, Fujishima M, Sadoshima S, Yoshida F, Shiokawa O, Ogata J, Omae T: Cerebral blood flow and tissue metabolism in experimental cerebral ischemia of spontaneously hypertensive rats with hyper-, normo-, and hypoglycemia. Stroke 1986;17:261–266.
- Simon GS, Dewey WL: Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J Pharmacol Exp Ther 1981;218:318–323.
- Kastin AJ, Pan W, Maness LM, Koletsky RJ, Ernsberger P: Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides 1999;20:1449–1453.
- Kastin AJ, Akerstrom V: Nonsaturable entry of neuropeptide Y into the brain. Am J Physiol 1999;276:E479–E482.
- Kastin AJ, Akerstrom V: Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999;289:219–223.
- Kastin AJ, Akerstrom V: Entry of CART into brain is rapid but not inhibited by excess CART or leptin. Am J Physiol 1999;277:E901–E904.
- Kastin AJ, Akerstrom V, Hackler L, Zadina JE: Phe13, Tyr19-Melanin-concentrating hormone and the blood-brain barrier: Role of protein binding. J Neurochem 2000;74:385–391.
- Kastin AJ, Akerstrom V, Hackler L: Agouti-related protein (83–132) aggregates and crosses the blood-brain barrier slowly. Metabolism 2000;49:1444–1448.
- Banks WA, DiPalma CR, Farrell CL: Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 1999;20:1341–1345.
- Maness LM, Banks WA, Kastin AJ: Persistence of blood-to-brain transport of leptin in obese leptin-deficient and leptin receptor-deficient mice. Brain Res 2000;873:165–167.
Banks WA, Clever CM, Farrell CL: Partial saturation and regional variation in the transport of leptin across the blood-brain barrier in normal weight mice. Am J Physiol 2000;278:E1158–E1165.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.